Keybank National Association OH cut its position in Zoetis Inc. (NYSE:ZTS – Free Report) by 34.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,908 shares of the company’s stock after selling 23,783 shares during the period. Keybank National Association OH’s holdings in Zoetis were worth $3,136,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ZTS. Wealthfront Advisers LLC increased its holdings in shares of Zoetis by 80.2% during the second quarter. Wealthfront Advisers LLC now owns 76,113 shares of the company’s stock valued at $5,469,000 after acquiring an additional 33,873 shares in the last quarter. Pacer Advisors Inc. raised its position in shares of Zoetis by 16.7% during the first quarter. Pacer Advisors Inc. now owns 165,570 shares of the company’s stock worth $19,572,000 after purchasing an additional 23,687 shares during the period. Diamond Hill Capital Management LLC Investment Advisor raised its position in shares of Zoetis by 21.5% during the second quarter. Diamond Hill Capital Management LLC Investment Advisor now owns 3,557,436 shares of the company’s stock worth $255,637,000 after purchasing an additional 629,974 shares during the period. Nykredit A S acquired a new position in shares of Zoetis during the second quarter worth approximately $10,042,000. Finally, Flossbach Von Storch SE bought a new position in shares of Zoetis in the 2nd quarter worth $302,601,000. 92.80% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
ZTS has been the subject of several research reports. JPMorgan Chase & Co. reduced their price target on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. Weiss Ratings upgraded shares of Zoetis from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, October 29th. TD Cowen lowered their price objective on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 25th. Citigroup lowered their price objective on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. Finally, Stifel Nicolaus dropped their price objective on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a research note on Thursday, August 20th. Eight analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $101.25.
Check Out Our Latest Stock Analysis on Zoetis
Zoetis Price Performance
ZTS stock opened at $83.65 on Monday. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.40 and a current ratio of 2.35. The business has a 50-day simple moving average of $76.28 and a two-hundred day simple moving average of $91.56. The company has a market capitalization of $33.99 billion, a P/E ratio of 14.23, a price-to-earnings-growth ratio of 1.21 and a beta of 0.67. Zoetis Inc. has a 52-week low of $68.77 and a 52-week high of $132.49.
Zoetis (NYSE:ZTS – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $1.75 EPS for the quarter, topping the consensus estimate of $1.51 by $0.24. The firm had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 85.90% and a net margin of 26.15%. The company’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.70 earnings per share. Research analysts expect that Zoetis Inc. will post 6.29 EPS for the current fiscal year.
Zoetis Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 annualized dividend and a dividend yield of 2.5%. Zoetis’s payout ratio is presently 36.05%.
Zoetis Company Profile
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
Recommended Stories
- Five stocks we like better than Zoetis
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
